The potential reclassification of cannabinoids, particularly at the federal level, is generating considerable anticipation within the sector. A shift away from Schedule I status, often viewed as outdated and hindering innovation, could unlock significant avenues for companies. Reduced regulatory restrictions, alongside greater access to banking and